Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Pharmaceutical Drug Class
|
| gptkbp:administeredBy |
Intravenous Injection
Oral Administration |
| gptkbp:affects |
Rapidly Dividing Cells
|
| gptkbp:canBe |
Adjuvant Therapy
Curative Therapy Neoadjuvant Therapy Palliative Therapy |
| gptkbp:cause |
Organ Toxicity
Secondary Malignancies |
| gptkbp:combines |
Radiation Therapy
immunotherapy Targeted Therapy |
| gptkbp:contraindication |
gptkb:Pregnancy
Severe Infection |
| gptkbp:discoveredIn |
20th Century
|
| gptkbp:example |
gptkb:Cyclophosphamide
gptkb:Cisplatin gptkb:Paclitaxel gptkb:Methotrexate Doxorubicin Vincristine 5-Fluorouracil |
| https://www.w3.org/2000/01/rdf-schema#label |
Chemotherapy Agents
|
| gptkbp:includes |
Alkylating Agents
Antimetabolites Antitumor Antibiotics Plant Alkaloids Platinum-Based Drugs Topoisomerase Inhibitors |
| gptkbp:mechanismOfAction |
Damage DNA
Inhibit Cell Division Interfere with Metabolism |
| gptkbp:monitors |
Oncologist
|
| gptkbp:prescribes |
gptkb:physician
|
| gptkbp:regulates |
gptkb:FDA
|
| gptkbp:requires |
Informed Consent
Blood Tests Kidney Function Tests Liver Function Tests |
| gptkbp:sideEffect |
gptkb:Nausea
gptkb:anemia Fatigue Immunosuppression Hair Loss Infection Risk |
| gptkbp:storage |
Controlled Room Temperature
|
| gptkbp:usedFor |
Cancer Treatment
|
| gptkbp:bfsParent |
gptkb:Systemic_Drug_Reaction
|
| gptkbp:bfsLayer |
7
|